Pfizer beats earnings estimates thanks to cost cuts
Pfizer beat Wall Street earnings estimates for the first three months of this year, fueled largely by an aggressive cost-cutting campaign.
Pfizer reported adjusted earnings per share of $0.92, higher than the $0.67 analysts polled by FactSet were expecting. The drugmaker also reported $13.7 billion in revenue, less than the $13.9 billion analysts were penciling in.
The company has cut an additional $1.2 billion in costs, with the goal of cutting $4.5 billion by the end of the year. Pfizer is trying to get leaner while it searches for its next blockbuster drug.
Management also reaffirmed its 2025 outlook, which “does not currently include any potential impact related to future tariffs and trade policy changes, which we are unable to predict at this time.”
Shares are modestly higher in premarket trading as prepared remarks from CFO David Denton suggest that the company is “currently trending toward the upper end” of its profit guidance, excluding any trade-related impacts.